Studies have found that obstructive sleep apnea (OSA) is associated with increased sympathetic activity, which activates our “fight or flight” response. This response, in turn, raises our heart rate. Sushmita Pamidi, MD, a sleep physician-scientist at McGill University, recently led a study on prediabetes, OSA, and cardiovascular disease, which was published in a supplement to the American Journal of Respiratory and Critical Care Medicine and presented at the American Thoracic Society (ATS) 2018 Conference in San Diego.
“Both prediabetes and higher resting heart rates have been linked to cardiovascular disease,” she says in a release. “We wanted to see if CPAP would lower resting heart rates both during the day and at night in this group of patients with abnormal glucose metabolism.”
Of 39 participants in this study, twice as many were randomly assigned to CPAP as an oral placebo for 14 days. All-night adherence to CPAP was assured by monitoring all participants in a sleep lab throughout the two weeks. Resting heart rates were measured 24 hours a day for the two weeks using a portable monitoring device.
The study found that those using CPAP had significantly lower resting heart rates throughout the day and night than those in the placebo arm of the study. The differences between the two groups were more pronounced during the second week of the trial.
“The effect of CPAP on resting heart rate is comparable to using beta blockers,” says Esra Tasali, MD, senior study author and director of the Sleep Research Center at the University of Chicago. Commonly prescribed for heart problems, beta blockers block stress hormones (such as adrenaline) that raise heart rates.
“OSA is exceedingly common among individuals with abnormal glucose tolerance,” Tasali adds, noting recent estimates indicate that 80% of those with OSA in the general US population are undiagnosed. “Our study is a first step in demonstrating that optimal treatment of sleep apnea reduces cardiovascular risk in those with prediabetes.”
Image courtesy ATS